Microbio Co., Ltd.
Taipei ExchangeTotal Valuation
Microbio Co., Ltd. carries a market capitalization of 10.56B, placing it among publicly traded companies globally. Its enterprise value stands at 10.22B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 10.56B |
| Enterprise Value | 10.22B |
Share Statistics
Microbio Co., Ltd. currently has 588.17M shares outstanding.
| Shares Outstanding | 588.17M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
The price-to-sales ratio is 5.76, and the price-to-book ratio stands at 2.12.
| PE Ratio | N/A |
| PS Ratio | 5.76 |
| PB Ratio | 2.12 |
| P/TBV Ratio | 1.08 |
| P/FCF Ratio | 70.58 |
| P/OCF Ratio | 127.87 |
Enterprise Valuation
| EV / Sales | 5.39 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | 61.45 |
Financial Position
Microbio Co., Ltd. maintains a current ratio of 4.30, meaning it holds 4.3x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 6.57, indicating elevated leverage, while an interest coverage ratio of -34.68 demonstrates limited ability to service its debt obligations.
| Current Ratio | 4.30 |
| Quick Ratio | 3.35 |
| Debt / Equity | 6.57 |
| Debt / EBITDA | -1.65 |
| Interest Coverage | -34.68 |
Financial Efficiency
| Return on Equity (ROE) | -15.23 |
| Return on Assets (ROA) | -5.77 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 4.72 |
Taxes
| Income Tax | 1.96M |
| Effective Tax Rate | N/A |
Stock Price Statistics
Microbio Co., Ltd.'s stock has declined approximately -20.22222% over the past 52 weeks. The 50-day moving average sits at 15.26, while the 200-day moving average is 18.52.
| Beta (5Y) | N/A |
| 52-Week Price Change | -20.22222% |
| 50-Day Moving Average | 15.26 |
| 200-Day Moving Average | 18.52 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Microbio Co., Ltd. generated 1.89B in revenue and converted that into -757.75M in net income, yielding earnings per share of -1.62. EBITDA reached -406.62M, while operating income came in at -406.62M.
| Revenue | 1.89B |
| Gross Profit | 753.46M |
| Operating Income | -406.62M |
| Pretax Income | -951.58M |
| Net Income | -757.75M |
| EBITDA | -406.62M |
| EBIT | -406.62M |
| Earnings Per Share (EPS) | -1.62 |
Balance Sheet
Microbio Co., Ltd. holds 2.65B in cash and equivalents against 670.59M in total debt, resulting in a net debt position of -707.74M. Total book value stands at 5.15B, with working capital of 2.61B providing operational flexibility.
| Cash & Cash Equivalents | 2.65B |
| Total Debt | 670.59M |
| Net Debt | -707.74M |
| Equity (Book Value) | 5.15B |
| Book Value Per Share | 8.73 |
| Working Capital | 2.61B |
Cash Flow
Microbio Co., Ltd. produced 85.27M in operating cash flow over the past twelve months. After subtracting -69.22M in capital expenditures, free cash flow totaled 16.05M - equivalent to 0.03 per share.
| Operating Cash Flow | 85.27M |
| Capital Expenditures | -69.22M |
| Free Cash Flow | 16.05M |
| FCF Per Share | 0.03 |
Margins
Microbio Co., Ltd. operates with a gross margin of 39.78, reflecting its pricing power and cost economics. The operating margin of -21.47 and net profit margin of -40.01 provide insight into operational efficiency.
| Gross Margin | 39.78 |
| Operating Margin | -21.47 |
| Pretax Margin | -50.24 |
| Profit Margin | -40.01 |
| EBITDA Margin | -21.47 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | 1.56 |
| FCF Yield | 1.42 |
Stock Splits
Microbio Co., Ltd.'s most recent stock split took place on August 29, 2024 with a 20:21 split ratio.
| Last Split Date | 8/29/2024 |
| Split Ratio | 20:21 |
Scores
Microbio Co., Ltd. posts an Altman Z-Score of 3.29, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 3.29 |